| Autor: |
Лисички, К., Кендерова, В., Ганева, М. |
| Zdroj: |
Pediatria; 2021, Vol. 61 Issue 2, p45-48, 4p |
| Abstrakt: |
Coronavirus disease - 2019 (COVID-19) was first identified in Wuhan, China. When compared with adults, children are less commonly symptomatic when having acute Covid-19 infection. In contrast to adults, most infected children appear to have a milder course and have better outcomes overall. Myositis is a rarely seen in COVID-19 patients. Its pathogenesis is probably multifactorial with direct myocyte invasion, toxin-mediated muscle damage, dysregulated immune response, and immunemediated mechanisms playing a role. We report the clinical case of a 7-year-old boy with COVID- 19 induced myositis with favorable outcome. At the fourth day of treatment the child is without clinical signs of myositis. At the sixth day creatine kinase levels normalized. The evolution of the myositis is favorable and corresponds to the reports in the literature. This was a second episode of myositis for the boy in the time frame of nine months. The first episode was defined as self-limiting benign acute childhood myositis with unknown trigger. COVID-19 myositis might develop at any time during the course of the infection, usually during the second week but it can be also the presenting symptom. COVID-19 induced myositis, although rare, might be accompanied by rhabdomyolysis and might be a life-threatening complication. Early recognition and effective management with intravenous hydration are crucial for the effective management and prevention of development of acute kidney failure. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
